Protection against feline leukemia virus challenge for at least 2 years after vaccination with an inactivated feline leukemia virus vaccine.
Twelve cats were vaccinated at 8 and 11 weeks of age with a commercially available inactivated FeLV vaccine (Nobivac FeLV, Intervet/Schering-Plough Animal Health). Eleven cats served as age-matched, placebo-vaccinated controls. All cats were kept in isolation for 2 years after vaccination and were then challenged with virulent FeLV to evaluate vaccine efficacy and duration of immunity. Cats were monitored for 12 weeks after challenge for development of persistent viremia using a commercial FeLV p27 ELISA. Persistent viremia developed in all 11 (100%) of the control cats, whereas 10 of 12 (83%) vaccinated cats were fully protected from persistent viremia following challenge. The results demonstrate that the vaccine used in this study protects cats from persistent FeLV viremia for at least 2 years after vaccination.
Jirjis
Faris F
FF
Intervet/Schering-Plough Animal Health, Elkhorn, NE 68022, USA.
Davis
Tamara
T
Lane
Jennifer
J
Carritt
Kari
K
Sweeney
Diane
D
Williams
James
J
Wasmoen
Terri
T
D000818:Animals; D002415:Cats; D005256:Leukemia Virus, Feline / Q000276:immunology*; D016582:Leukemia, Feline / Q000517:prevention & control*; D013047:Specific Pathogen-Free Organisms; D014611:Vaccination; D015164:Vaccines, Inactivated / Q000276:immunology; D014765:Viral Vaccines / Q000276:immunology*; D014766:Viremia
D015164:Vaccines, Inactivated; D014765:Viral Vaccines